免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
98.5分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
实体瘤过继性细胞治疗：黑色素瘤中的现状与下一代疗法
英文原题：Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
查看英文原题
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Lifileucel（TIL（肿瘤浸润淋巴细胞），TIL）近期获得 FDA 批准，用于转移性黑色素瘤患者，是首种获批用于实体瘤的细胞疗法。本文讨论 TIL 作为新标准治疗（SOC）的推广实施，以及其他即将出现的新型细胞疗法。
展开英文摘要原文
Lifileucel or TIL has recently been FDA approved for metastatic melanoma patients as first cell therapy for a solid tumor. We discuss roll-out of TIL as new SOC and other upcoming new cell therapies.
论文信息
- 作者
- Haanen J、Los C、Phan GQ、Betof Warner A
- 第一作者单位
- Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.Netherlands
- 通讯作者单位
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
- 文献类型
- 综述
- 期刊
- American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2024 Jun
- 原文标识
- PubMed 38776509 · DOI 10.1200/EDBK_431608